SIGA: Siga Technologies Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
161 institutions reported holding $124.93M of Siga Technologies Inc on Form 13F (183 the quarter before). 14 opened a new position and 35 sold out. Shares held by institutions: +3%.
| Largest holders | Shares | Value |
|---|---|---|
| BlackRock, Inc. | 4,186,282 | $15.24M |
| DIMENSIONAL FUND ADVISORS LP | 2,719,568 | $9.90M |
| AltraVue Capital, LLC | 2,327,144 | $8.47M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,712,701 | $6.23M |
| AMERICAN CENTURY COMPANIES INC | 1,506,065 | $5.48M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,474,817 | $5.37M |
| GEODE CAPITAL MANAGEMENT, LLC | 1,417,092 | $5.16M |
| FIRST WILSHIRE SECURITIES MANAGEMENT INC | 1,339,883 | $4.88M |
| AQR CAPITAL MANAGEMENT LLC | 1,245,992 | $4.54M |
| STATE STREET CORP | 1,133,989 | $4.13M |
Clinical trial readouts
1 Phase 2 or 3 trials by Siga Technologies Inc with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-01-01 (est.) | Tecovirimat | Smallpox | Phase 2 | 100 | Enrollment complete | NCT04957485 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.